13F filer · CIK 1560009
Versant Venture Management, LLC
San Francisco, CA · filing since Q4 2014 · last filing Aug 12, 2026
Reported value
$162.6M
+$21.2M vs prior
Positions
8
New / sold out
0 / 0
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $11.9M
Top-10 weight
100.0%
Biggest buys vs Q1 2026
No new or increased positions this quarter.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Jade Biosciences, Inc. | -534,037 | -35.0% | $-11.9M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc.COMMON STOCK | 3,180,780 | $77.0M | 47.34% |
| 2 | Century Therapeutics, Inc.COMMON STOCK | 12,166,109 | $29.8M | 18.33% |
| 3 | Jade Biosciences, Inc.COMMON STOCK | 991,783 | $22.0M | 13.55% |
| 4 | Lenz Therapeutics, Inc.COMMON STOCK | 2,656,888 | $15.1M | 9.28% |
| 5 | Contineum Therapeutics, Inc.COMMON STOCK | 542,628 | $8.9M | 5.47% |
| 6 | CRISPR Therapeutics AGCOMMON SHARES | 148,831 | $8.1M | 4.99% |
| 7 | Skye Bioscience, Inc.COMMON STOCK | 2,007,704 | $1.4M | 0.86% |
| 8 | Tempest Therapeutics, Inc.COMMON STOCK | 269,772 | $299.4K | 0.18% |